Assai's Q2: Trade-Down Resilience and a Bold Bet on In-Store Pharmacies
Deleveraging progress and new growth avenues offset a pressured consumption backdrop.
ASAI3.SA · Earnings Call · 2026-08-07
Resilient Execution Amid Macro Pressure
In a quarter where Brazilian consumers remain squeezed, Sendas Distribuidora (ASAI3.SA) turned in a steady operational performance. The company grew customer flow by 2.4% on a total base, gained 0.3pp of market share in cash-and-carry, and took average ticket down by about 2% as shoppers traded down. CEO Belmiro Gomes framed it as “It's not a quarter with demand acceleration. It's about resilience and economic evolution.” — Belmiro de Gomes, CEO · 2026-08-07 The trade-down is most acute among low income households, but Assai is leaning into the shift with its own-label push. "We have a consumer that's really willing to have a brand trade down," Gomes noted, pointing to the company's strength in attracting cost-conscious shoppers. This is a continuation of a theme seen in prior quarters. In late 2024, Gomes highlighted the company's focus on gaining share through margins rather than volume: “the company has 40% margin. We can notice that the market when it comes to competitive advantages, but the objective is always to gain more margin.” — Belmiro de Gomes, CEO · 2024-11-08 That discipline remains visible now, as the company preserved EBITDA margin while accelerating customer traffic.The Pharma Angle: A New Growth Avenue
The most striking new initiative is Assai Pharma, the in-store drugstore chain launched after a legal change allowed drugstores inside food retail. Management sees a massive opportunity: a CapEx of under R$400k per store, with 250 units potentially by the mid-term. Anderson Castilho explained the economics: “The CapEx of drug store is like 1/3 of than what we would have [indiscernible], et cetera. So our view is that we have to really work on the legal changes there and because that's -- we have an investment of about BRL 100 million with the sales potential of a store. It's like 1.5 store revenue.” — Anderson Castilho, Unknown (likely executive or senior management) · 2026-08-07 This is part of a broader new initiatives wave that also includes private label expansion and digital partnerships. The private label is already contributing to margin gains, and management expects to double its SKU count by 2027. "We're not just waiting for the macro environment to get better," Gomes said, emphasizing that these initiatives are designed to extract more value from the 40 million monthly visitors. The drug store is particularly interesting because it leverages existing store traffic and infrastructure. "Most of the Assai stores have available space to be able to add a drug store without having to implement any major revolutions in the assortment," Castilho added. The company already has two stores operational and expects to have 250 by the mid-term, with a total investment of around BRL 100 million.Deleveraging and Financial Discipline
Deleveraging remains a core focus. Net debt fell to 2.7x EBITDA, with a BRL 1.4 billion cash generation in the last 12 months. CFO Rafael Sachete highlighted the reduction in discounted receivables and cost of debt. The company is also benefiting from tax credits. debt level is dropping, and cash availability covers 2 years of maturities. "We have a very solid, very healthy cash position," Sachete said. The company ended the quarter with BRL 7 billion in cash and undrawn facilities, up 20.9% year-over-year. This deleveraging is not just a financial goal; it's a strategic enabler for future growth. "The company is very confident that things will continue to drop over the next quarters," Gomes noted. Prior calls reflected the same focus on cash generation, but the current quarter shows tangible results. As Gomes put it in his final remarks:Overall, Assai's Q2 2026 demonstrates that even in a pressured macro, disciplined execution and bold adjacency bets can protect margins and drive structural improvement. The market will be watching how the pharma rollout and private label ramp progress over the next quarters.We have a challenging consumer environment. There's a macroeconomic issue that, of course, is not under our control entirely, but the company is really focused with different initiatives to improve our core and working... our biggest asset is the customer flow monthly.